Dr. Reddy Lab: Launches Vigabatrin powder in US

Shares of Dr. Reddy rose close to 2 per cent intraday post the announcement that the company has launched Vigabatrin Powder for oral solution in the US market.

Dr. Reddy’s Laboratories has launched Vigabatrin Powder for Oral Solution, USP in 500 mg packet. The medication is a therapeutic equivalent of Sabril Powder for Oral Solution, USP, approved by the U.S. Food and Drug Administration (USFDA). Dr. Reddy's Vigabatrin Powder for Oral Solution, USP is available in 500 mg per packet in count size of 50 per carton. According to IMS Health, Sabril brand had US sales of approximately US$274 million MAT for the most recent 12-months ended in June 2019.

Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

At closing on Tuesday, it was trading at Rs. 2,554.90 per share, 1.77 per cent higher. The stock hit an intraday high of Rs. 2,563.05 and intraday low was Rs. 2,519.55. Its 52-week high was Rs. 2,965.2 and 52-week low was Rs. 2,065.3 per share on the BSE.